DavidRGreeleyMDFAAN

PubMed

• 1 citations
  Naturalistic assessment of everyday multitasking in Parkinson's disease with and without mild cognitive impairment.
  Maureen Schmitter-Edgecombe, Katelyn Brown, Reanne Cunningham Chilton, Nicole Whiteley, David Greeley
  The Clinical Neuropsychologist. 2024-11-01
• 1 citations
  ALSUntangled #66: antimycobacterial antibiotics.
  Ellen S Pierce, Paul Barkhaus, Morgan Beauchamp, Mark Bromberg, Gregory T Carter
  Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2023-08-01
• 4 citations
  A Comparison of Functional Abilities in Individuals with Mild Cognitive Impairment and Parkinson's Disease with Mild Cognitive Impairment Using Multiple Assessment Met...
  Maureen Schmitter-Edgecombe, Courtney McAlister, David R. Greeley
  Journal of the International Neuropsychological Society. 2021-09-06

Other

• Current Therapeutic Approaches to the Treatment of Parkinson’s disease. 
  Demos R, Setter SM, Greeley DR, Johnson K, Washington Pharmacy
• Neuroimmunophilin Ligands: A Novel Treatment for Parkinson’s disease. 
  Harrell J, Setter SM, Greeley DR, Consult Pharm
• Potential Advances in the Treatment of Parkinson’s Disease. 
  Setter SM, Iltz JL, Greeley DR, Advances in Pharmacy
• Normal Pressure Hydrocephalus. 
  Neumiller JJ, Neumiller JJ, Gates BJ, Setter SM, Greeley DR
  http://www.uspharmacist.com/content/t/neurology/c/10438/
• A Study to Assess the Sensitivity and Specificity of the Wearing-Off Questionnaire-9. 
  Novartis, The Sensitivity and Specificity of the 9-item Wearing-off Questionnaire
• A Registry Study to Evaluate the Implications of Motor Fluctuations in Parkinson’s Disease on Chronic Therapy. 
  Bertek
• A 12-week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter, Fixed Dose-Response Study to Evaluate the Efficacy and Safety of 10, 20 and 40 ... 
  Kyowa
• A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 or 40 mg Doses of Istradefylline as Treatment for Parkinson’s Disease in Patients with Motor Response ... 
  Kyowa
• A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan 1 mg bid in Patients with Parkinson’s ... 
  Merck KGaA, Protocol #018
• A Phase II, Double- Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Efficacy and Safety of 40 mg/day Istradefylline as Monotherapy. 
  Kyowa, Protocol #051
• A 12-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of Ropinirole CR (ReQuip®) in Patients with Restless Legs Syndrome. 
  GlaxoSmithKline, Protocol # 205
• A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Naratriptan (Amerge®) for the Treatment of Migraine in Subjects who ... 
  Glaxo Wellcome
• A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Trial of Oxcarbazepine (Trileptal®) as Adjunctive Therapy in Patients. 
  Novartis
• Blockade of the GP IIB/IIIA Receptor to Avoid Vascular Occlusion. 
  SmithKline Beecham
• Oral Almotriptan (Axert®) vs. Oral Sumatriptan (Imitrex®) in a Double-Blind, Randomized, Parallel Group Study of Cost-Effectiveness and Quality of Life in Migraine. 
  Pharmacia & Upjohn
• The Effects of Citicoline Clinical Outcome and the Evolution of Lesion Volume in Human Stroke. 
  Interneuron
• A Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Acetaminophen, Aspirin and Caffeine (Excedrin Migraine®). 
  McNeil, Headache
  http://www.blackwell-synergy.com/doi/abs/10.1111/j.1526-4610.2006.00351_4.x
• Cervical Dystonia – Patient Registry for Observation of Botox Efficacy (CD-PROBE). 
  Allergan
• A Long-Term, Open-Label, Flexible-Dose Study of the Efficacy and Safety of Sumanirole in Patients with Idiopathic Restless Legs Syndrome. 
  Pharmacia
• A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Fixed Dose Response Study Comparing the Efficacy and Safety of Pramipexole (Mirapex®). 
  Pharmacia
• An Evaluation of the Safety and Efficacy of Altropane for the Detection of Parkinsonian Syndrome in Patients with Movement Disorders. 
  Boston Life Sciences
• An Open-Label Study to Demonstrate Equivalence of Twice Daily Dosing of Galantamine (Razadyne®) Compared to Once Daily Dosing of Vitamin E in Regard to Compliance. 
  Janssen
• A Double-Blind, Placebo-Controlled, Dose Ranging Study of Nefiracetam in Patients with Post-Stroke Depression. 
  Daiichi
• A Multicenter, Double-Blind, Placebo-Controlled Study of the Tolerability and Effect of Entacapone (Comtan®). 
  Novartis
• A Multi-center, Randomized, Double-blind, Parallel Group, Multiple Dose Comparison Study of Valdecoxib 20mg, Valdecoxib 40mg, Sumatriptan 50mg and Placebo. 
  Pharmacia
• Join now to see all